Background: Asthma, an inflammatory disease of the respiratory tract, is one of the
most frequent causes of referral to emergency departments. The aim of this study is to evaluate the
efficacy of montelukast as a member of LTRAs for the improvement of pulmonary function and
clinical symptoms of patients with asthma.
Methods: The study was conducted on 80 patients with acute mild- moderate asthma, divided randomly
into two groups of 40 subjects. A double-blind clinical trial was conducted on asthmatic patients
who encounter an acute phase asthma attack. The experimental group received two montelukast
5 mg chewable tablets at arrival, accompanied by standard mild-moderate asthma treatment
consisting of oxygen and nebulization with albuterol 2.5 mg and ipratropium bromide 0.5 mg
in 3 doses for 60 minutes. The control group received standard mild-moderate asthma treatment
plus placebo chewable tablets at the beginning without any leukotriene inhibitors. Pulmonary function
tests, hemodynamic variables and Borg Dyspnea Scale were evaluated and analyzed at 0, 30,
60, 90 and 150 minutes in both case and control groups.
Results: No significant differences were observed between the case and the control group in terms
of PEFR and FEV1 measurements during the study at different time points [P > 0.05]. There were
no significant differences in terms of hemodynamic variables [blood pressure, pulse and respiration
rate, pressure of oxygen in arterial blood] and Borg Dyspnea Scale in both groups as well.
Conclusion: The study findings showed that the montelukast administration in mild-moderate
acute asthma attack setting had no significant impact on pulmonary function tests and clinical
symptoms of the studied patients rather than standard asthma treatment.